Anti-Cancer Agents in Medicinal Chemistry

(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Michelle Prudhomme  
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France

Back

Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer

Author(s): Tristan M. Sissung, Silja Thordardottir, Erin R. Gardner, William D. Figg.

Abstract:

Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate.

Keywords: Prostate cancer, thalidomide, lenalidomide, CC-5013, angiogenesis inhibition

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 9
ISSUE: 10
Page: [1058 - 1069]
Pages: 12
DOI: 10.2174/187152009789735017
Price: $58